Kyowa Hakko Kirin Co., Limited

Kirin Beer Kabushiki Kaisha

University of Massachusetts

Hematech, LLC

Barbara A Osborne

James M Robl

Yoshimi Kuroiwa

Richard A Goldsby

Isao Ishida

Kazuma Tomizuka

Poothappillai Kasinathan

Stacy E Ferguson

Philippe Collas

Katherine L Knight

Eddie Sullivan

Furkan Ayaz

Sara Jones

P Kasinathan

The invention relates to an exopolysaccharide (EPS), compositions comprising EPS and methods of use, including for treating and preventing disorders, such as inflammatory disorders.

Exopolysaccharide for inflammatory disease

The present invention relates to a method of producing an ungulate having both copies of the IgM heavy chain (mu) rag-1 and/or rag-2 gene eliminated from its genome. Animals which have IgM, rag-1 and/or rag-2 eliminated from their genome are unable to conduct the gene rearrangements that are necessary to generate the antigen receptors of B- or T-lymphocytes, and therefore will not develop native B- or T-cells. Because they are unable to produce B- and T-lymphocytes, these IgM, rag-1, or rag-2 ungulates cannot reject human hematopoietic stem cell preparations, and B- and T-lymphocytes which develop therefrom. Therefore, the present invention also involves injecting into IgM, rag-1, and/or rag-2 deficient ungulates, in utero or shortly after birth, human B- and T-lymphocytes whose immune systems produce human immunoglobulin that can be processed for therapeutic uses in humans.

Production of ungulates, preferably bovines that produce human immunoglobulins

The invention features novel methods for the production of large quantities of xenogenous antibodies, such as human antibodies. Preferably, this result is effected by inactivation of IgM heavy chain expression and, optionally, by inactivation of Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of xenogenous antibodies (e.g., non-bovine antibodies), preferably human antibodies.

Transgenic ungulates capable of human antibody production

The present invention relates to the production of a transgenic bovine which comprises a genetic modification that results in inactivation and loss of expression of its endogenous antibodies, and the expression of xenogenous antibodies, preferably human antibodies. This is effected by inactivation of the IgM heavy chain expression and, optionally, by inactivation of the Ig light chain expression, and by the further introduction of an artificial chromosome which results in the expression of non-bovine antibodies, preferably human antibodies.

Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates

Transgenic bovines capable of human antibody production

Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin

Growing community of inventors

Leverett, MA, United States of America

Barbara A Osborne